Eukaryotic translation initiation factor 4 gamma 2 (EIF4G2)

Eukaryotic translation initiation factor 4 gamma 2 (EIF4G2, also called DAP5, p97, or NAT1) is a large scaffolding protein in the eIF4G family that regulates translation initiation—the control point for protein synthesis in eukaryotic cells[1][2][3][4]. Unlike canonical eIF4G1, EIF4G2 lacks the N-terminal binding sites for eIF4E and PABP, thus it does not directly mediate classic cap-dependent translation, but rather functions predominantly in cap-independent translation via internal ribosome entry site (IRES)-mediated mechanisms or other non-canonical pathways[1][3][4]. It is required for efficient translation of certain mRNAs during stress, apoptosis, mitosis, and viral infection. EIF4G2 is critically involved in diverse physiological processes, including apoptosis, cell survival, differentiation, embryonic development, and the control of cell proliferation[1][3]. Its loss or dysregulation has been linked with defective cell cycle control, differentiation, and disease processes including cancer and neurological disorders[1][3][4]. Although not a classic receptor or enzyme drug target, its centrality to translation control makes it relevant as a potential therapeutic target in precision medicine for cancer and infection[1][3][4]. No direct clinical inhibitors or therapeutically relevant drugs are currently documented for EIF4G2.

Other names

DAP5OK/SW-cl.75eIF-4-gamma 2eIF-4G 2eIF4G 2DAP-5NAT1p97Death-associated protein 5AAG1aging-associated protein 1eukaryotic translation initiation factor 4G-like 1